Initial Statement of Beneficial Ownership (3)

FORM 3	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES	OMB APPROVAL OMB Number: 3235-0104 Estimated average burden hours per response... 0.5
	Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person ^*

Madison Greg

2. Date of Event Requiring Statement (MM/DD/YYYY) 2/8/2014

3. Issuer Name and Ticker or Trading Symbol

KERYX BIOPHARMACEUTICALS INC [KERX]

(Last) (First) (Middle)

C/O KERYX BIOPHARMACEUTICALS, INC., 750 LEXINGTON AVENUE

4. Relationship of Reporting Person(s) to Issuer (Check all applicable)

_____ Director _____ 10% Owner
___ X ___ Officer (give title below) _____ Other (specify below)
See Remarks /

(Street)

NEW YORK, NY 10022

(City) (State) (Zip)

5. If Amendment, Date Original Filed (MM/DD/YYYY)

6. Individual or Joint/Group Filing (Check Applicable Line)

_ X _ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1.Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock	76547 ⁽¹⁾ ⁽²⁾	D

*Table II - Derivative Securities Beneficially Owned ( e.g.* , puts, calls, warrants, options, convertible securities)**
1. Title of Derivate Security (Instr. 4)	2. Date Exercisable and Expiration Date (MM/DD/YYYY)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
1. Title of Derivate Security (Instr. 4)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	4. Conversion or Exercise Price of Derivative Security		6. Nature of Indirect Beneficial Ownership (Instr. 5)
Stock Options (Right to Buy)	2/8/2015 ⁽³⁾	2/8/2024	Common Stock	80000	$15.21	D
Stock Options (Right to Buy)	2/8/2014 ⁽⁴⁾	2/8/2024	Common Stock	115000	$15.21	D

Explanation of Responses:
( 1)	The shares of restricted stock vest as follows: 25,000 on February 8, 2014; 20,000 on February 8, 2015; and the remaining 40,000 in equal quarterly installments from February 8, 2015 through February 8, 2017.
( 2)	Shown net of the sale of 8,453 shares of common stock on February 10th, 2014 at a price of $15.34 per share to satisfy Mr. Madison's income tax withholding obligation upon the vesting of 25,000 shares of restricted stock on February 8, 2014. Mr. Madison had no discretion with respect to such sale, which was transacted automatically in accordance with the Issuer's corporate policies regarding the vesting of restricted stock. Following the sale, Mr. Madison beneficially owns 76,547 shares of common stock of which 60,000 are restricted shares.
( 3)	The options vest as follows: 26,667 on February 8, 2015; and the remaining 53,333 in equal quarterly installments from February 8, 2015 through February 8, 2017.
( 4)	The options will vest as follows: (i) 15,000 upon the first commercial sale of Zerenex(TM) (ferric citrate coordination complex) within 90 days of marketing approval by the FDA, (ii) 30,000 upon reported net sales for Zerenex of (greater than or equal to)$25 million in a calendar quarter, (iii) 30,000 upon reported net sales for Zerenex of greater than or equal to $50 million in a calendar quarter, and (iv) 40,000 upon reported net sales for Zerenex of greater than or equal to $75 million in a calendar quarter.

Remarks:
Executive Vice President and COO

Reporting Owners
Reporting Owner Name / Address	Relationships
Reporting Owner Name / Address	Director	10% Owner	Officer	Other
Madison Greg C/O KERYX BIOPHARMACEUTICALS, INC. 750 LEXINGTON AVENUE NEW YORK, NY 10022			See Remarks

Signatures
/s/ Gregory P. Madison		2/13/2014
^** Signature of Reporting Person		Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
*	If the form is filed by more than one reporting person, see Instruction 5(b)(v).
**	Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note:	File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.